Urinary Tract Infection in Specific Populations and Controversies in Disease Management

Narrative Summary of Selected Presentations given at the OM Pharma/Vifor Pharma URO-VAXOM® Summit, held in Buenos Aires, Argentina, on 26th–27th April 2014

Susan Contreras,1 Juan Guillermo Corrales Riveros,2 Enrique Patricio Ubertazzi,3 Peter Tenke,4 Joost J. van Middendorp5

1. Hospital Militar Dr Carlos Arvelo, Caracas, Venezuela
2. Servicio de Urología, Instituto Nacional de Salud del Niño, Lima, Perú
3. Urogynaecology Section, Italian Hospital of Buenos Aires, Buenos Aires, Argentina
4. Department of Urology, South-Pest Hospital, Budapest, Hungary
5. Research Director, Stoke Mandeville Spinal Foundation, National Spinal Injuries Centre, Stoke Mandeville Hospital, Aylesbury, UK

Disclosure: The authors are global consultants of OM/Vifor Pharma Company, Meyrin, Switzerland.
Acknowledgements: Assistance was provided by Ewen Legg, ApotheCom ScopeMedical.
Support: The publication of this article was funded by OM/Vifor Pharma. The views and opinions expressed are those of the authors and not necessarily those of OM/Vifor Pharma.
Citation: EMJ Urol. 2014;1(Suppl 2):29-40.

Summary

This educational summit, supported by an independent grant from OM/Vifor Pharma, brought together experts in the field of urology and gynaecology from Europe and Latin America to meet and discuss the cutting edge management of patients suffering from recurrent urinary tract infections (rUTIs). The meeting included plenary lectures as well as workshops and interactive sessions, allowing delegates and presenters to debate the most pressing international and local issues in the field.

The physiological and anatomical changes associated with pathological and non-pathological conditions, such as pregnancy, can modify both the risk of contracting a UTI and the recommended treatment. Risk factors also evolve across the lifespan of a patient affecting the management of UTIs. Here we discuss specific challenges in disease management across a number of patient subgroups at higher risk of UTI.

Comments are closed.